Sistema de Salut de Catalunya
Institut Català de la Salut
[Arrobas Velilla T] Virgen Macarena University Hospital, Seville, Spain. [Fernández Prendes C] Analysis and Clinical Biochemistry Service, Laboratori Clínic Metropolitana Nord, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Amigó Grau N] Department of Basic Medical Sciences, Rovira i Virgili University, Reus, Spain. Center for Biomedical Research in Diabetes and Associated Metabolic Diseases (CIBERDEM), Instituto de Salud Carlos III, Madrid, Spain. Biosfer Teslab, Reus, Spain. [Calmarza P] Service of Clinical Biochemistry, Miguel Servet University Hospital, Zaragoza, Spain. Centre for Networked Research in Cardiovascular Diseases (CIBERCV), Instituto de Investigacion Sanitaria Aragon, Zaragoza, Spain. [Camós Anguila S] Service of Clinical Biochemistry- Laboratori Clínic Girona, Hospital Universitari de Girona Dr. Josep Trueta, Institut Català de la Salut (ICS), Girona, Spain. [Candás Estébanez B] Laboratori Clínic, Hospital of Barcelona, Barcelona, Catalunya, Spain. Facultat de Medicina, UVic-UCC, Vic, Spain. Facultat de Ciències, UVic-UCC, Vic, Spain. [Castro Castro MJ, Ceacero D] Biochemistry Core, Laboratori Clínic Territorial Metropolitana Sud, Bellvitge University Hospital, L'Hospitalet de Llobregat, Spain
Hospital Universitari de Girona Dr Josep Trueta
2025-05-26T07:14:24Z
2025-05-26T07:14:24Z
2025
2025-03-03
Colesterol; Lipoproteïna A
Colesterol; Lipoproteína(a)
Cholesterol; Lipoprotein(a)
Cardiovascular diseases keep being the leading cause of mortality in Spain. Efforts should be intensified to identify new risk factors that may contribute to increasing cardiovascular risk. Lipoprotein(a) (Lp(a)) has been associated with a higher risk for developing aortic valve stenosis, heart failure, ischemic stroke, ischemic heart disease and peripheral arterial disease. Hyperlipoproteinemia(a) is a common health problem. Between 10 and 30 % of the world population have Lp(a) values exceeding 50 mg/dL. The scientific evidence provided in the recent years confirms an independent association between Lp(a) and the risk for having an arteriosclerotic cardiovascular event. This finding, added to the emergence of new specific therapies for reducing Lp(a) has raised interest in the quantification of this lipoprotein. The objective of this paper was to perform a review of the evidence available to identify the patients who will benefit from undergoing Lp(a) testing and determine the recommended quantification methods, the desirable concentrations, and the role of Lp(a) determination in reclassifying the cardiovascular risk of patients.
Article
Published version
English
Colesterol; Lipoproteïna A; CHEMICALS AND DRUGS::Lipids::Membrane Lipids::Sterols::Cholesterol; CHEMICALS AND DRUGS::Lipids::Lipoproteins::Lipoprotein(a); DISEASES::Cardiovascular Diseases; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Diagnosis::Diagnostic Techniques and Procedures::Clinical Laboratory Techniques; COMPUESTOS QUÍMICOS Y DROGAS::compuestos policíclicos::compuestos con anillos de fusión::esteroides::colestanos::colestenos::colesterol; COMPUESTOS QUÍMICOS Y DROGAS::lípidos::lipoproteínas::lipoproteína; ENFERMEDADES::enfermedades cardiovasculares; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::diagnóstico::técnicas y procedimientos diagnósticos::técnicas de laboratorio clínico
De Gruyter
Advances in Laboratory Medicine;6(1)
https://doi.org/10. 1515/almed-2024-0090.
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
